Aug 24, 2022
Nanotechnology is an evolving and innovative technology set to transform healthcare dynamics to its core with promising applications. Advancements in nanoscience have led to the emergence of a new generation of nanostructures that are employable in the healthcare industry to a much larger extent. With the unique ab...
Read More...
Aug 19, 2022
Currently, more than 70 companies are evaluating 235+ AAV vectors in gene therapy at different stages to improve the therapeutics segment.
Read More...
Aug 17, 2022
Interoperability solutions in healthcare are improving the patient experience by streamlining care delivery. Major companies in the market
Read More...
Aug 12, 2022
The expected launch of newly approved Molluscum Contagiosum therapies such as VP-102 and SB206 are expected to drive the therapeutics segment in the coming years.
Read More...
Aug 10, 2022
Globally, Telepsychiatry demand is rising at an immense pace. Key companies are working in the market to fulfill their needs. Due to various benefits, the market is
Read More...
Aug 08, 2022
The Dystrophic Epidermolysis Bullosa treatment market has a promising outlook. Various gene therapies in different stages are in the pipeline.
Read More...
Aug 05, 2022
Currently, the PML Therapeutics pipeline mainly comprises early phase assets. Limited companies are investigating in PML treatment options.
Read More...
Aug 03, 2022
The role of Artificial Intelligence in Mental Health is growing at an immense pace. The application of AI is providing immense benefit to user
Read More...
Aug 01, 2022
Several late-stage therapies developed by leading players for generalized myasthenia gravis treatment are expected to enter the therapeutics market
Read More...
Jul 29, 2022
Currently, there is no effective curative ADPKD treatment. However, leading companies in the therapeutics segment are evaluating novel drugs.
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper